# IRLAB Therapeutics > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/irlabtherapeuticsa). ## Overview IRLAB Therapeutics is a Swedish biopharmaceutical company focused on discovering and developing novel treatments for Parkinson's disease and other central nervous system (CNS) disorders. Originating from Nobel Prize-winning research, the company leverages its proprietary Integrative Screening Process (ISP) to create first-in-class drug candidates. IRLAB's pipeline includes several promising compounds targeting different stages and symptoms of Parkinson's, with the potential to significantly improve patient outcomes. The company is listed on the Nasdaq Stockholm and is recognized for its strategic focus on CNS disorders. ## Products & services • Mesdopetam (IRL790) for levodopa-induced dyskinesias • Pirepemat (IRL752) for balance and fall frequency in Parkinson's • IRL757 for apathy in neurodegenerative disorders • IRL1117 for basic symptoms of Parkinson's • Proprietary Integrative Screening Process (ISP) platform - **Parkinson's Disease Treatments** (70%) — Includes drugs targeting various stages and symptoms of Parkinson's. - **CNS Disorder Treatments** (20%) — Drugs for other central nervous system disorders beyond Parkinson's. - **Research Platform Licensing** (10%) — Licensing of the proprietary ISP research platform. - Mesdopetam (IRL790) for levodopa-induced dyskinesias - Pirepemat (IRL752) for balance and fall frequency in Parkinson's - IRL757 for apathy in neurodegenerative disorders - IRL1117 for basic symptoms of Parkinson's - Proprietary Integrative Screening Process (ISP) platform ## Customers IRLAB Therapeutics primarily serves the pharmaceutical and healthcare sectors, focusing on partnerships with large pharmaceutical companies and research institutions. Their customers include organizations seeking innovative treatments for Parkinson's and CNS disorders. The company's drug candidates are of interest to entities involved in clinical trials and those looking for licensing opportunities. IRLAB's unique research platform also attracts collaborations for drug discovery and development. - **Pharmaceutical Companies** (primary) — They buy drug candidates for CNS disorders to expand their treatment portfolios. - **Research Institutions** (secondary) — They collaborate on clinical trials and research for Parkinson's treatments. - **Licensing Partners** (emerging) — They license the ISP platform for drug discovery and development. - Pharmaceutical companies seeking new CNS disorder treatments - Research institutions interested in Parkinson's disease - Entities involved in clinical trials for CNS disorders - Organizations looking for licensing opportunities for novel drugs - Collaborators interested in the ISP research platform ## Geography IRLAB Therapeutics is headquartered in Gothenburg, Sweden, and operates primarily within the European market. The company is listed on the Nasdaq Stockholm, which provides it with a strong presence in the Nordic region. While its research and development activities are centered in Sweden, IRLAB collaborates internationally, particularly with regulatory bodies in the US and Europe for clinical trials. This geographic focus allows IRLAB to leverage regional expertise and regulatory frameworks to advance its drug candidates. - Headquartered in Gothenburg, Sweden - Listed on Nasdaq Stockholm, enhancing Nordic presence - Collaborates with US and European regulatory bodies - Focus on European market for clinical trials and partnerships - Leverages regional expertise in CNS disorder treatments ## Strategy IRLAB's strategic priorities include advancing its drug candidates through clinical trials, particularly focusing on mesdopetam and pirepemat. The company aims to secure strategic partnerships and collaborations to fund and support its R&D efforts. Another key priority is to expand its patent portfolio to protect its innovative treatments and extend market exclusivity. IRLAB is also focused on enhancing its proprietary ISP platform to continue generating first-in-class drug candidates. - **Advance clinical trials for mesdopetam** (medium-term) — To treat levodopa-induced dyskinesias effectively - **Expand patent portfolio** (short-term) — To protect innovations and extend exclusivity - **Secure strategic partnerships** (medium-term) — To fund and support R&D efforts - Advance mesdopetam and pirepemat through clinical trials - Secure strategic partnerships for R&D funding - Expand patent portfolio for market exclusivity - Enhance ISP platform for new drug candidate generation - Focus on CNS disorders for strategic growth ## Risks IRLAB faces several risks, including the inherent uncertainties of drug development, such as clinical trial failures and regulatory hurdles. The company is also exposed to financial risks due to its reliance on external funding and partnerships for R&D activities. Market competition from other CNS disorder treatments poses a threat to its market share. Additionally, changes in regulatory environments, particularly in the US and Europe, could impact the approval and commercialization of its drug candidates. - **Clinical trial failures** [critical] — Could delay or halt drug development - **Regulatory hurdles** [high] — Impact approval and commercialization - **Financial dependency** [high] — Relies on external funding for R&D - Clinical trial failures could delay drug development - Regulatory hurdles may impact drug approval - Financial dependency on external funding for R&D - Market competition from other CNS treatments - Regulatory changes in the US and Europe ## Accounting IRLAB applies the Swedish Annual Accounts Act and IFRS, with specific attention to revenue recognition from research collaborations and licensing. Revenue is recognized in line with the costs of the activities they cover, which can impact reported income. The company does not use fair value measurements for financial instruments, which are valued at accrued acquisition value. This approach may affect the comparability of financial statements with peers using fair value accounting. Additionally, the timing of milestone payments and grants can lead to fluctuations in quarterly financial results. - **Revenue recognition** - **Financial instruments valuation** - **Milestone payments timing** - Revenue recognized in line with activity costs - No fair value measurements for financial instruments - Accrued acquisition value used for financial assets - Timing of milestone payments affects quarterly results - IFRS applied for financial reporting consistency --- *Last updated: 2026-08-11T04:04:53.563317+00:00*